This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
Table 13a. Predictors of Disease Response or Survival—Clinical Diagnostic Tests That Predict Response to Thalidomide: Summary
Prognostic Factor |
Number of studies indicating significant correlation with tumor response/ total number of studies indicating factor |
Number
of studies indicating significant correlation with survival/ total number
of studies indicating factor |
Cytogenetics |
Correlation with response=2/2
(Barlogie, 200143; Shaughnessy, 2003133) |
Correlation with survival=1/1
(Shaughnessy, 2003133) |
Chromosome 13 abnormality |
Correlation with response=2/3
(Barlogie, 2002109; Shaughnessy, 2003133) No correlation=1/3
(*Attal, 2004 (ASH 535)108) |
Correlation with survival=4/4
(Barlogie, 2002109; Mileshkin, Biagi, et al., 200399; Shaughnessy, 2003133; Singhal, 199935) |
Albumin |
Some correlation with response=2/3
(Dimopoulos, 200494; Yakoub-Agha, 200260) No correlation=1/3
(Shaughnessy, 2003133) |
Correlation with survival=3/3
(Shaughnessy, 2003133; Singhal, 199935; Yakoub-Agha, 200260) |
Beta 2 microglobulin (B2M) |
Some correlation with response=4/5
(Garcia-Sanz, 200495; Shaughnessy, 2003133; Schutt, 200587; *Attal, 2004 (ASH 535)108) No correlation=1/5
(Neben, Moehler, Egerer, et al., 200152 |
Correlation with survival=3/3
(Mileshkin, Biagi, et al., 200399; Shaughnessy, 2003133; Schutt, 200587) |
Hemoglobin |
No correlation=1/1
(Neben, Moehler, Egerer, et al., 200152) |
No correlation=2/2
(Dimopoulos, 200170; Mileshkin, Biagi, et al., 200399) |
Platelets |
Correlation with response=1/1
(Garcia-Sanz, 200495) |
|
Serum lactose dehydrogenase (LDH) |
Correlation with response=3/3
(Dimopoulos, 200494; Shaughnessy, 2003133; Singhal, 199935) |
Correlation with survival=4/4
(Dimopoulos, 200170; Dimopoulos, 200494; Mileshkin, Biagi, et al., 200399; Shaughnessy, 2003133) |
C Reactive Protein (CRP) |
Correlation with response=2/2
(Shaughnessy, 2003133; Singhal, 199935) |
Correlation with survival=1/1
(Shaughnessy, 2003133) |
IgA isotype |
Correlation with response=1/1
(Yakoub-Agha, 200260) |
Correlation with survival=1/1
(Yakoub-Agha, 200260) |
Light chain type |
Correlation with response=1/1
(Dimopoulos, 200170) |
Correlation with survival=1/1
(Dimopoulos, 200170) |
Plasma cell labeling index (PCLI) |
Correlation with response=2/2
(Barlogie, 200143; Singhal, 199935) |
|
Abbreviations: *=abstract, BM=bone marrow, B2M=beta-2 microglobulin, FGF=Fibroblast Growth Factor, CRP=C-reactive protein, CT=chemotherapy, CTD=cyclophosphamide + Thalidomide + Dexamethasone, d=day, Dex=Dexamethasone, dL=deciliter, EFS=event free survival, FISH=fluorescence in situ hybridization, f/u=followup, g=grams, HDCT=high dose chemotherapy, HR=hazard ratio, IFN=interferon, IU=international units, L=liter, LDH=?, med=median, mo=month, ml=milliliter, NS=not stated, OS=overall survival, PCLI=plasma cell labeling index, PPR=paraprotein reduction, pt(s)=patient(s), RCT=randomized controlled trial, RR=relative risk, SCT=stem cell transplant, Thal=Thalidomide, tx'd=treated, ULN=upper limit of normal, VEGF=Vascular endothelial growth factor, vs.=versus, w/=with, yr=year
Return to Document
Proceed to Table 13b
|
540 Gaither Road Rockville, MD 20850